TGFB1 and breast carcinoma: Studies have shown that the number of canonical myofibroblasts (myCAFs, Subset 2) and VEGF+ CAFs (vCAFs, Subset 3) cells in breast cancer tissues decreased significantly after transforming growth factor-β(TGF-β) antibody blockade, indicating that these two subsets are very sensitive to this treatment.